HER2+ Breast Cancer

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

Debu Tripathy, MD, provided an update on neoadjuvant strategies in HER2-positive breast cancer at the 2017 Miami Breast Cancer Conference.

Michael F. Press, MD, PhD, discusses issues with the ASCO-CAP guidelines on assessment of HER2 amplification by fluorescence in situ hybridization testing.

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses data supporting the elimination of anthracyclines in HER2-positive breast cancer treatment.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.

Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

Adding pertuzumab (Perjeta) to trastuzumab (Herceptin) and chemotherapy reduced the risk of recurrence of invasive disease or death in patients with HER2-positive early breast cancer, according to findings from the phase III APHINITY study.

Julia White, MD, The Ohio State University Comprehensive Cancer Center, discusses brain metastases in patients with HER2-positive breast cancer.

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses the potential advantages of optical imaging for patients with HER2-positive breast cancer.